Cancer trageting DDS using hollow albumin nanoparticles with structural flexibility

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20719
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0801:Pharmaceutical sciences and related fields
• Research Institution: Wakayama Medical University
• Principal Investigator: Ikeda Mayumi 和歌山県立医科大学, 薬学部, 助教 (90965708)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: DDS / albumin nanoparticle / cancer targeting

Outline of Final Research Achievements

Albumin nanoparticles consisting of albumin and cationic polymers were synthesized by a layer-by-layer method with calcium nanoparticles as the core. The albumin nanoparticles with a hollow structure were successfully prepared by reacting the albumin nanoparticles with a chelate. The cellular uptake efficiency of the hollow albumin nanoparticles was higher than the non-hollow albumin nanoparticles and albumin monomers. The biodistribution study in a mouse model of carcinoma showed that the hollow albumin nanoparticles migrated into tumor tissue more readily than the albumin monomers, while their migration into the liver was suppressed.

Free Research Field

薬物送達学

Academic Significance and Societal Importance of the Research Achievements

アルブミンナノ粒子は生体適合性に優れており、かつ腫瘍に積極的に取り込まれることからがんDDSとして注目されている。本研究により合成した中空型のアルブミンナノ粒子は、構造柔軟性を獲得したことにより従来のアルブミンナノ粒子よりも腫瘍との親和性が向上し、かつ肝臓による捕捉を抑制できた。したがって、従来型よりも優れたがんへの薬物送達キャリアとなり、抗がん剤の有効性の向上や副作用の軽減が期待される。